Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...